绥美凯纳入医保目录了吗？

It is a drug for the treatment of AIDS. Trimecavir is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

In January 2018, Suimeikan officially landed in the Chinese market. Has Suimeikan been included in the medical insurance catalog?

According to Medical Companion Travel, Suimeikai has not been included in the medical insurance since it was launched in China not long ago, and it is a self-pay drug for patients. Since Suimeikai is an imported original drug in China, it is very expensive and most patients cannot afford it. Therefore, many patients choose Suimeikai, which is launched in India. Suimeikai, produced by the Indian company Emcure, comes in a box of 30 tablets and sells for about RMB 1,000. The price cannot be determined due to the floating exchange rate. Please consult Medical Travel for the specific price.

Side effects of patients using Suimeikai: depression, abnormal dreams, headache, dizziness, diarrhea, nausea, and fatigue.

Precautions for patients using Suimeikai:

1. Trimax should not be taken with multivalent ion drugs (magnesium, aluminum, calcium); if necessary, it should be taken two hours before or after Trimax. It is prohibited to use it in combination with poly2, Felite or rifampicin.

2. Hepatitis B patients taking Suimeikai may aggravate hepatitis.

3. Suimeikai can be used only if the HLA-B*5701 test is negative. Not suitable for patients with poor renal function. Multivalent ion drugs (magnesium, aluminum, calcium) need to be taken at least two hours apart from this drug.

It has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.

Recommended hot articles: /newsDetail/71707.html